The European Union is on the cusp of a historic transformation in pharmaceutical regulation. On June 4, 2025, the Council of the European Union agreed on its position regarding the sweeping “pharma package”—a major legislative initiative aimed at making the EU pharmaceutical sector more fair, competitive, and resilient. With negotiations now set to begin with the European Parliament, these changes may soon reshape how medicines are developed, regulated, and accessed across the EU.
Why This Matters for Medicines Development Professionals
The pharma package marks the most significant revision to EU pharmaceutical legislation in over 20 years. For professionals working in regulatory affairs, clinical trials, and medical affairs, these proposed changes could impact everything from approval timelines and data protection to strategic planning for market access.
What’s in the Pharma Package?
The package includes two core proposals:
- A regulation laying down EU procedures for the authorization and supervision of medicinal products and rules for the European Medicines Agency (Council of the EU, 2025b).
- A directive establishing a Union code for medicinal products (Council of the EU, 2025c).
Key objectives of the legislation:
- Ensure equitable access to medicines across all EU member states.
- Enhance the competitiveness of the pharmaceutical industry by reducing regulatory burdens.
- Improve medicine supply chain security and transparency.
- Enforce stronger environmental rules in pharmaceutical manufacturing and distribution (Council of the EU, 2025a).
Council’s Key Amendments
The Council’s mandate—approved on June 4—introduces several notable changes (Council of the EU, 2025a):
- Regulatory Data Protection (RDP): Innovative medicines will benefit from eight years of data protection.
- Market Protection: One additional year of protection is granted, extendable to two years if specific criteria are met.
- Obligation to Supply: A new rule gives EU member states the power to require companies to provide sufficient quantities of medicine to meet national needs.
- Transferable Exclusivity Vouchers: These may be used only in the fifth year of RDP and only if product sales do not exceed €490 million annually in the preceding four years.
- Bolar Exemption Expansion: Expands the IP exemption for generics and biosimilars to include procurement submissions, enabling earlier entry of generics and biosimilars (Council of the EU, 2025c).
Encouraging Broader Access and Innovation
In its original 2023 proposal, the European Commission aimed to encourage pharmaceutical companies to launch products in all EU countries. For instance, it proposed reducing the standard regulatory data protection from eight to six years, with an option for an additional two years if the product was launched across all member states (Council of the EU, 2025b).
Similarly, medicines for rare diseases could qualify for nine years of market exclusivity, extended further if they met high unmet needs or achieved broad distribution.
What’s Next?
The Council’s agreed position now enters the trilogue phase—negotiations with the European Parliament. Final legislation will follow after legal and linguistic revisions.
Tailored Learning for a Changing Regulatory Landscape
As the EU shifts toward a more agile, equitable, and competitive pharmaceutical framework, professionals must be ready to adapt. At GMDP Academy, students can tailor their continuing professional development by enrolling in only the modules that meet their current needs—making it easier to stay aligned with evolving responsibilities and regulatory expectations.
Three modules especially relevant to the EU pharma package include:
- Module 5: Regulatory Affairs, Drug Safety and Pharmacovigilance
Provides in-depth understanding of EU regulatory frameworks, global harmonization, and the implications of changes to regulatory data protection and supply chain obligations. - Module 6: Medical Affairs as a Strategic Business Partner
Equips professionals to align Medical Affairs with broader corporate and regulatory strategy—essential as new EU rules emphasize public access, transparency, and environmental responsibility. - Module 7: Leadership in Medical Affairs
Focuses on the mindset and competencies needed to lead through industry change—particularly important as organizations adjust to more complex compliance environments and higher public expectations.
References
- Council of the European Union. (2025, June 4). ‘Pharma package’: Council agrees its position on new rules for a fairer and more competitive EU pharmaceutical sector. https://www.consilium.europa.eu/en/press/press-releases/2025/06/04/pharma-package-council-agrees-its-position-on-new-rules-for-a-fairer-and-more-competitive-eu-pharmaceutical-sector/
↳ Council of the EU, 2025a - Council of the European Union. (2025, June 2). Proposal for a Regulation of the European Parliament and of the Council laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing rules governing the European Medicines Agency (ST 9286/2025 INIT). https://data.consilium.europa.eu/doc/document/ST-9286-2025-INIT/en/pdf
↳ Council of the EU, 2025b
Council of the European Union. (2025, June 2). Proposal for a Directive on the Union code relating to medicinal products for human use (ST 9285/2025 INIT). https://data.consilium.europa.eu/doc/document/ST-9285-2025-INIT/en/pdf
↳ Council of the EU, 2025c
Disclaimers
- The material in these reviews is from various public open-access sources, meant for educational and informational purposes only
- Any personal opinions expressed are those of only the author(s) and are not intended to represent the position of any organization(s)
- No official support by any organization(s) has been provided or should be inferred
